Compare Deere & Company (DE) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Deere & Company vs 10X Genomics Inc — how do they compare? Deere & Company trades at $617 (market cap $166.81B), while 10X Genomics Inc trades at $58.69 (market cap $7.61B). The key difference: Deere & Company is far larger — about 21.9× 10X Genomics Inc's market cap, and Deere & Company pays a 1.05% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals.
| DE | TXG | |
|---|---|---|
Market Cap | $166.81B | $7.61B |
Sector | Industrials | Health |
52-Week High | $662.49 | $58.57 |
52-Week Low | $439.11 | $11.34 |
Enterprise Value | $221.63B | $7.14B |
Dividend Yield | 1.05% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Deere & Company (DE) trades at $609.28, down 1.86% on the day, amid mixed signals. The stock shows a bullish technical trend with strong moving averages, but oscillators are neutral. Recent earnings have consistently beaten expectations, with Q1 2026 EPS of $6.55 surpassing the $5.70 estimate. Revenue declined to $44.67B in 2025, with net income margin at 10.33%. Analyst consensus is a Moderate Buy, with a price target of $669.79, implying potential upside. The company maintains a solid balance sheet with $8.48B in cash, though debt levels remain elevated.
The outlook for DE is cautiously optimistic, driven by earnings beats and analyst confidence, but tempered by revenue declines and agricultural cycle risks. Investment opportunity lies in the valuation gap to the consensus target, while key risks include weak North American demand and margin pressure highlighted in recent industry reports. The stock's performance hinges on upcoming Q3 2026 earnings on August 20, 2026.
TXG trades at $58.57, up 12.57% in 24 hours, reflecting strong momentum. The stock is technically bullish with moving averages supporting the uptrend, though RSI levels suggest overbought conditions. Fundamentally, the company shows improving trends with Q2 2026 earnings beating estimates and revenue growth, yet remains unprofitable with a negative net income margin. Recent news highlights collaborations and acquisitions expanding its genomic capabilities.
Outlook is mixed; analyst consensus is neutral with a $46 price target below current levels, indicating caution despite recent beats. Key risks include sustained losses and competitive pressures, but operational cash flow growth and strategic expansions offer potential upside for patient investors focused on long-term biotech innovation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Deere & Company
Deere is the world's leading manufacturer of agricultural equipment, producing some of the most recognizable machines in the heavy machinery industry. The company is divided into four reportable segments: production and precision agriculture, small agriculture and turf, construction and forestry, and John Deere Capital. Its products are available through an extensive dealer network, which includes over 1,900 dealer locations in North America and approximately 3,700 locations globally. John Deere Capital provides retail financing for machinery to its customers, in addition to wholesale financing for dealers, which increases the likelihood of Deere product sales.
Read more on DE →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
